Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single-Dose Denosumab in Japanese Postmenopausal Women
NCT03822078Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2003
- Primary completion
- Dec 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing Placebo with Denosumab (2 arms). Primary endpoint: Number of Participants With Adverse Events up to 9 months. Started Sep 2003; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03822078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822078.